Any U.S. company operating in regulated overseas market must abide by the Foreign Corrupt Practices Act (FCPA), which prohibits U.S. companies from bribing foreign officials to secure an improper business advantage.  This is particularly true in the pharmaceutical/medical device sector, which has been a recent target of DOJ and SEC investigations.  Although pharmaceutical giants such as Pfizer and Novartis have paid millions of dollars to settle FCPA claims, smaller, local companies are just as vulnerable.

Please join Jack Harrington, chair of our International Regulation, Enforcement & Compliance practice, for an informative presentation about how to protect your company with regard to the FCPA.  Jack will address the HIA-LI Manufacturing Committee on Wednesday, January 25, 2017 at 8:30 a.m. on the FCPA and its impact on the Long Island manufacturing economy.  Open to all HIA members, the meeting will take place at 225 Wireless Blvd., Hauppauge.  Register here.